MALLINCKRODT MEDICAL FILES OCTREOSCAN 111 NDA FOR ABDOMINAL TUMOR IMAGING
MALLINCKRODT MEDICAL FILES OCTREOSCAN 111 NDA FOR ABDOMINAL TUMOR IMAGING on Oct. 22. A combination of Sandoz' somatostatin analog octreotide (Sandostatin) radiolabeled with Indium 111, Octreoscan is designed for early detection and evaluation of very small tumors and metastatic sites in the lung, breast and lymph nodes. The NDA is specifically for use of OctreoScan in the detection of tumors originating in neuro-endocrine cells, particularly in the abdomen, Mallinckrodt parent IMCERA said Oct. 23. More than 80% of neuro-endocrine tumors have receptors for somatostatin, studies show. These types of tumors may be good candidates for octreo tide therapy, Mallinckrodt said. In an Oct. 22 presentation at the Oppenheimer & Co. health care conference in New York City, Mallinckrodt President and CEO Ray Holman called the agent "one of the most exciting products to be developed in nuclear medicine" and predicted OctreoScan 111 "will actually begin a new generation of nuclear medicine products." Mallinckrodt described OctreoScan 111 as the first radiolabeled small peptide submitted for FDA approval specifically for tumor imaging. The company is pursuing a number of other applications for the agent. Mallinckrodt developed the radiolabeled small peptide agent in conjunction with Sandoz Pharma (Basel) and scientists from the University Hospital Dijkzigt in Rotterdam, the Netherlands. The product was introduced in Holland for gastrointestinal indications earlier in 1992. Mallinckrodt Medical also plans to register the tumor imaging agent for approval in Canada and Japan.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth